The India diabetes market size was valued at INR 316 billion in 2023, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16% during the forecast period of 2024-2032, with the values likely to rise from INR 366.56 billion in 2024 to INR 1201.74 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetes is a condition where the body cannot use the insulin produced effectively or the pancreas does not produce enough insulin at all. Insulin is a hormone produced to regulate glucose in the body. There are two categories of diabetes, type 1 and type 2. Type 1 diabetes is based on the amount of insulin produced by the body and type 2 diabetes is based on the management of insulin by the body. Common symptoms include frequent thirst, blurred vision, fatigue, unintentional weight loss and constant urge to urinate.
The diabetes incidence rate in India stands at around 10.1 crores in 2023. The India diabetes market value is driven by the rising awareness among the patients about the symptoms of diabetes, and its ill effects on health, which has majorly intensified the diagnosis and increased the drug treatment rates in the country.
Rapid urbanization and developing healthcare infrastructure are also aiding the industry growth of diabetes in India. In addition to this, extending pharmaceutical contract manufacturing, low-cost drug production, and the introduction of advanced technologies have further accelerated the growth of diabetes market in India. In July 2023, the Indian Institute of Technology (IIT) Bhilai and Shiv Nadar University revealed “smart insulin”, which contains an extended period of insulin release that lasts up to 2 days, far greater than the average 12-hour duration of regular insulin.
To meet the high India diabetes market demand, leading health platforms for diabetes like the BeatO App have announced their physical clinic collaborations. After launching 5 clinics across Delhi-NCR, the company visions to spread across Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat, and Odisha in the next 6 months. Akums Drugs and Pharmaceuticals Limited also received approval for its triple combination diabetes treatment which includes Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500. Therefore, the market is expected to witness significant growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Doses Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The India diabetes market growth is driven by the launch of programs like National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD), which has been launched by the government of India and works on delivering glucometer and drugs for diabetes to the patients. As a part of this program, the region is also experiencing the set-up of new district clinics and community health centers to promote early diagnosis and prevention of the condition. Movements like Fit India, Khelo India and several yoga related activities are also promoted by the Ministry of AYUSH to promote physical activity in all generations.
Moreover, the increasing partnerships amongst private and state-owned entities will also contribute significantly to the India diabetes market share and deliver better solutions to diabetic and pre-diabetic patients. Promotional activities to eat healthy are also advocated by prominent institutions like FSSAI. Eat Right Initiative, Safe and Nutritious Food at Home and ‘Aaj se thoda kum’ awareness initiatives are some of the prime examples. Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the masses are also set to receive generic medicines like insulin at affordable prices.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Treatment Type||
|Breakup by Doses Form||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 India Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2017-2032)
5.2 India Diabetes Epidemiology by Diabetes Type (2017-2032)
5.3 India Diabetes Epidemiology by Gender (2017-2032)
5.4 India Diabetes Epidemiology by Treatment Rate (2017-2032)
6 India Diabetes Market Overview
6.1 India Diabetes Market Historical Value (2017-2023)
6.2 India Diabetes Market Forecast Value (2024-2032)
7 India Diabetes Market Landscape
7.1 Diabetes Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetes Therapeutics: Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Diabetes Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 India Diabetes Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 India Diabetes Market Segmentation
11.1 India Diabetes Market by Type
11.1.1 Market Overview
11.1.2 Type 1 Diabetes
11.1.3 Type 2 Diabetes
11.2 India Diabetes Market by Treatment Type
11.2.1 Market Overview
11.3 India Diabetes Market by Doses Form
11.3.1 Market Overview
11.3.2 Tablets and Capsules
11.3.4 Creams and Gels
11.4 India Diabetes Market by Route of Administration
11.4.1 Market Overview
11.5 India Diabetes Market by End User
11.5.1 Market Overview
11.5.3 Speciality Clinics
11.5.4 Homecare Settings
11.6 India Diabetes Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospitals Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Sun Pharmaceutical Industries Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Biocon Limited
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Dr. Reddy's Laboratories Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Novo Nordisk India Pvt. Ltd.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5 Sanofi India Limited
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Eli Lilly and Company (India) Pvt. Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7 Johnson & Johnson Private Limited
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 Abbott India Limited
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9 Glenmark Pharmaceuticals Ltd.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10 AstraZeneca Pharma India Limited
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.11 Lupin Limited
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.12 Torrent Pharmaceuticals Ltd.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.13 Merck Limited
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.14 Cadila Healthcare Limited
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.15 Wockhardt Limited
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
19 Diabetes - Distribution Model (Additional Insight)
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about INR 316 billion in 2023, driven by rising incidence of diabetes cases in the region.
The market is anticipated to grow at a CAGR of 16% during the forecast period of 2024-2032, likely to reach a market value of INR 1201.74 billion by 2032.
The market demand is driven by increasing government and private institution driven awareness initiatives among the patients about the symptoms and treatment of diabetes.
The current market trend is driven by the advent of new technical inventions. In July 2023, IIT Bhilai and Shiv Nadar University collaborated to develop a “smart insulin”.
Diabetes can be divided into type 1 diabetes and type 2 diabetes.
Treatment types include insulin-based and non-insulin-based, among others.
Dose forms include tablets and capsules, injections, creams and gels, among others.
Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.
Major end users include hospitals, speciality clinics, and homecare settings, among others.
The route of administration can be oral or parenteral.
Key players involved in the market are Sun Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy's Laboratories Ltd., Novo Nordisk India Pvt. Ltd., Sanofi India Limited, Eli Lilly and Company (India) Pvt. Ltd., Johnson & Johnson Private Limited, Abbott India Limited, Glenmark Pharmaceuticals Ltd., AstraZeneca Pharma India Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Merck Limited, Cadila Healthcare Limited and Wockhardt Limited.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.